Active ingredients: entrectinib
What it is used for
Non-small cell lung cancer (NSCLC),Rozlytrek is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours are ROS1-positive.,Solid tumours,Rozlytrek is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that:, have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,, are metastatic or where surgical resection is likely to result in severe morbidity, and, have either progressed following treatment or have no satisfactory alternative therapy.,This indication was approved via the provisional approval pathway, based on objective response rate and duration of response in single-arm trials. Full registration for this indication depends on verification and description of clinical benefit in confirmatory trials.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Size 0 hard capsules with orange body and cap with 'ENT 200' imprinted in blue on the body.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2021. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient entrectinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.